Showing results (61-70 of 119) with videos related to

Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1989
On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia GroupB Löwenberg, R Zittoun, H Kerkhofs, et al.
Cancer|September 15, 1988
Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative GroupC F Verschraegen, U R Kleeberg, J Mulder, et al.
Lancet (London, England)|August 1, 1992
Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVONP Sonneveld, B G Durie, H M Lokhorst, et al.
Leukemia|November 1, 1995
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG)T de Witte, S Suciu, M Peetermans, et al.
Leukemia|January 1, 1994
A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative GroupH H Gerhartz, R Marcus, A Delmer, et al.
European Journal of Cancer & Clinical Oncology|March 1, 1989
Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantationJ Hermans, S Suciu, T Stijnen, et al.
Leukemia|January 1, 1994
Treatment of patients with acute promyelocytic leukemia. The EORTC-LCG experience. EORTC Leukemia Cooperative GroupR Willemze, S Suciu, F Mandelli, et al.
Annals of Hematology|April 1, 1992
A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative GroupR Willemze, N van der Lely, H Zwierzina, et al.
European Journal of Cancer (Oxford, England : 1990)|February 23, 2002
Statistical methodology of phase III cancer clinical trials: advances and future perspectivesR Sylvester, M Van Glabbeke, L Collette, et al.
Seminars in Oncology|June 1, 1987
Cytosine arabinoside for induction, salvage, and consolidation therapy of adult acute lymphoblastic leukemiaP Stryckmans, T De Witte, N Bitar, et al.
Pageof 12